Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population

Hematologic Malignancy Clinical Trial

— PC004  

Official title:

A Study to Evaluate the Usability, Adherence and Diagnostic Performance of a Novel System to Non-Invasively Detect Severe Neutropenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04889937
• Other study ID #: MDACC Protocol ID: 2021-0061
• Status: Recruiting
• Start date: September 7, 2021
• Est. completion date: July 2023

Study information

• Verified date: March 2023
• Source: Leuko Labs, Inc.
• Contact: Alvaro Sánchez-Ferro, MD, PhD
• Phone: +1 617 419 0974
• Email: alvaro[@]leuko.io
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Single-site non-significant risk, open-label clinical investigation designed to validate the usability, adherence, and preliminary diagnostic performance of a novel technology to detect neutropenia. Study participants will be managed as per the standard of care practice with a baseline and nadir visit including laboratory determinations. Participants will also be evaluated with the device at both time points and with daily measurements during the two-week period in between.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: July 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 39 Years

Eligibility

Inclusion Criteria

1. Study subjects, or their parent/legal guardian for subjects <18 years, must be able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations. Subjects between the ages of 7 and 17.9 years must provide assent.

2. Male or Female aged 7 years to 65 years.

3. Adults (> 18 years) diagnosed Diagnosed with Hodgkin/Non-Hodgkin Lymphoma or breast cancer.

4. Children and adolescents (7 - 18 years) with liquid or solid tumors.

5. Scheduled treatment with cytotoxic chemotherapy with an associated high/intermediate risk of neutropenia (table 1) 30.

6. Able (in the investigator's opinion) and willing to comply with all study requirements.

Exclusion Criteria

1. Participants with amputations, congenital malformations, or any severe abnormalities of the hands as determined by the investigator.

2. Participants with a history of vasculitis, Raynaud syndrome, scleroderma, mixed connective tissue disease, or any other rheumatologic systemic condition that could produce microcirculatory changes in the nailfold.

3. Participants with circulating tumor cells in previous or current lab determinations.

4. Adult (>18 years) participants with leukemia of all types and pediatric (7-18 years) participants with leukemia that are either not in remission or in the minimal residual disease category.

5. Participants with any condition producing significant tremor (e.g., essential tremor, Parkinson´s disease, dystonic tremor).

6. Unstable participants (pediatric or adults) or adult participants with hypotension (systolic blood pressure <90 and diastolic blood pressure < 60mmHg).

7. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

8. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrolment.

Related Conditions & MeSH terms

• Hematologic Malignancy
• Hematologic Neoplasms

Intervention

Device:
• PointCheck
PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose

Locations

Country	Name	City	State
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
Leuko Labs, Inc.	Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Disorders, M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Predictive capacity of PointCheck	An exploratory analysis about the number of days before the second lab determination that PointCheckTM detected severe neutropenia will be investigated in those participants with severe neutropenia at the nadir visit. Also, exploratory analysis will be conducted in patients developing febrile neutropenia (axillary temperature =100.4°F and grade III/IV neutropenia documented in the lab report) during the study to evaluate how many days before the appearance of fever the device detected severe neutropenia during the at home phase of the study.	Up to three-weeks
Other	Diagnostic performance for a second cutoff	The preliminary diagnostic accuracy to detect grade III neutropenia according to CTCAE V5 (<1000 ANC/mm3) 13 measured by the sensitivity and the specificity will be the evaluated with reference to the corresponding laboratory measures acquired at the nadir (follow up) visit.	Up to three-weeks
Other	Clinical Utility Assessment	Survey completed by the clinical team at the baseline visit assessing the clinical utility of PointCheckTM	Up to three-weeks
Primary	Usability of PointCheck	The study will confirm if participants can acquire good quality videos in a home like setting.; The System Usability Scale (0-100 higher scored indicate a better usability) will be completed by the participants after completing the follow up visit.	Up to three-weeks
Secondary	Accuracy of PointCheck	The preliminary diagnostic accuracy to detect grade IV neutropenia according to CTCAE V5 (<500 ANC/mm3) measured by the sensitivity and the specificity will be the evaluated with reference to the corresponding laboratory measures acquired at the nadir (follow up) visit.	Up to three-weeks
Secondary	Repeatability of PointCheck	The % agreement of the device to classify neutropenia compared to the laboratory reference will be established	Up to three-weeks
Secondary	Number of participants with device-related adverse events as assessed by CTCAE v5.0	The number (and %) of AEs, SAEs and their relationship with the device use will be the safety endpoint	Up to three-weeks
Secondary	Adherence to PointCheck	The number of days that the participant used the device will be used to evaluate adherence.	Up to three-weeks

External Links

•   Sponsor website